SCHEMBL14981304

SCHEMBL14981304

CCOc1cc(N2CCCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC2CC2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ZAP70 P43403 10/20 0.61
▸ ALK Q9UM73 9/20 0.57
▸ INSR P06213 4/20 0.57
▸ IGF1R P08069 4/20 0.57
▸ EGFR P00533 3/20 0.56
▸ BMPR1B O00238 1/20 0.55
▸ PLK4 O00444 1/20 0.55
▸ STK25 O00506 1/20 0.55
▸ RIOK3 O14730 1/20 0.55
▸ CHEK1 O14757 1/20 0.55
▸ CASK O14936 1/20 0.55
▸ AURKA O14965 1/20 0.55
▸ GAK O14976 1/20 0.55
▸ DCLK1 O15075 1/20 0.55
▸ MUSK O15146 1/20 0.55
▸ EPHB6 O15197 1/20 0.55
▸ PDPK1 O15530 1/20 0.55
▸ MAP3K13 O43283 1/20 0.55
▸ DAPK3 O43293 1/20 0.55
▸ MAP3K7 O43318 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912095 0.94 EGFR (0.64) ZAP70ALKINSRIGF1REGFR
SCHEMBL10209551 0.91 ZAP70 (0.61) ZAP70ALKINSRIGF1REGFR
SCHEMBL12729041 0.91 ZAP70 (0.61) ZAP70ALKINSRIGF1REGFR
SCHEMBL12781068 0.91 ZAP70 (0.71) ZAP70ALKINSRIGF1REGFR
SCHEMBL12780213 0.90 ZAP70 (0.74) ZAP70ALKINSRIGF1REGFR
SCHEMBL12893014 0.90 ZAP70 (0.71) ZAP70ALKINSRIGF1REGFR
SCHEMBL12729031 0.89 ZAP70 (0.75) ZAP70ALKINSRIGF1REGFR
SCHEMBL12729023 0.88 ZAP70 (0.71) ZAP70ALKINSRIGF1REGFR
SCHEMBL12781283 0.86 ALK (0.71) ZAP70ALKINSRIGF1REGFR
SCHEMBL10208645 0.85 ALK (0.68) ZAP70ALKINSRIGF1REGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2287156-B1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-05-29 — — EP disclosed
Send feedback